Using milrinone to prevent complications after heart surgery in very premature infants
2/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - DCC Resubmission
['FUNDING_OTHER'] · RESEARCH TRIANGLE INSTITUTE · NIH-10801049
This study is looking at whether giving a heart medicine called milrinone can help very premature babies avoid a serious heart problem after they have surgery to fix a blood vessel called the patent ductus arteriosus (PDA).
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH TRIANGLE INSTITUTE (nih funded) |
| Locations | 1 site (RESEARCH TRIANGLE PARK, UNITED STATES) |
| Trial ID | NIH-10801049 on ClinicalTrials.gov |
What this research studies
This research investigates the use of milrinone, a cardiovascular medication, to prevent Post-Ligation Cardiac Syndrome (PLCS) in extremely preterm infants who undergo surgical closure of a patent ductus arteriosus (PDA). The study will involve a multicenter randomized controlled trial where infants will receive either milrinone or a placebo to assess its effectiveness in reducing the incidence of PLCS. By closely monitoring the infants' health outcomes, the research aims to provide clearer evidence on the benefits of milrinone in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are extremely preterm infants, particularly those who are less than 4 weeks old and require surgical closure of a patent ductus arteriosus.
Not a fit: Patients who are not extremely preterm or do not require surgical intervention for patent ductus arteriosus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of serious complications following heart surgery in extremely preterm infants, leading to better overall health outcomes.
How similar studies have performed: Preliminary data suggest that milrinone may be effective in reducing PLCS, indicating that this approach has potential based on earlier findings, though it has not been rigorously tested in a randomized controlled trial.
Where this research is happening
RESEARCH TRIANGLE PARK, UNITED STATES
- RESEARCH TRIANGLE INSTITUTE — RESEARCH TRIANGLE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAS, ABHIK — RESEARCH TRIANGLE INSTITUTE
- Study coordinator: DAS, ABHIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.